Risk factors for Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 408-414

  Rubenstein, Joel H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adipokines; Esophageal neoplasms; Genetic loci; Obesity; Risk assessment

Indexed keywords

PEPTIDE;

ABDOMINAL OBESITY; BARRETT ESOPHAGUS; CANCER INCIDENCE; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENDER; GENETIC RISK; GENETIC VARIABILITY; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TOBACCO USE; COMPLICATION; ESOPHAGEAL NEOPLASMS; MASS SCREENING; OBESITY; SEX DIFFERENCE; SMOKING;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; MASS SCREENING; OBESITY; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84902281620     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000084     Document Type: Review

References (34)

1. Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011; 106:254-260.
2. Rubenstein JH, Taylor JB. Meta-analysis: The association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32:1222-1227.
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142-146.
4. Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11:1399.e7-1412.e7.
5. Derakhshan MH, Robertson EV, Fletcher J, et al. Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. Gut 2012; 61:337-343.
6. Rubenstein JH, Morgenstern H, Chey WD, et al. Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut 2014; 63:230-235.
7. Greer KB, Thompson CL, Brenner L, et al. Association of insulin and insulinlike growth factors with Barrett's oesophagus. Gut 2012; 61:665-672.
8. Garcia JM, Splenser AE, Kramer J, et al. Circulating inflammatory cytokines and adipokines are associated with Barrett's esophagus: A case-control study. Clin Gastroenterol Hepatol 2014; 12:229-238.
9. Thompson OM, Beresford SAA, Kirk EA, et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity 2010; 18:2204-2211.
10. Kendall BJ, Macdonald GA, Hayward NK, et al., Study of Digestive Health. Leptin and the risk of Barrett's oesophagus. Gut 2008; 57:448-454.
11. Francois F, Roper J, Goodman AJ, et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008; 57:16-24.
12. Rubenstein JH, Morgenstern H, McConell D, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology 2013; 145:1237-1244.
13. Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett's esophagus: An analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012; 142:744-753.
14. Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: A pooled analysis from the international BEACON consortium. Gut 2013; 62:1684-1691.
15. Lagergren K, Mattsson F, Lagergren J. Abdominal fat and male excess of esophageal adenocarcinoma. Epidemiology 2013; 24:465-466.
16. Cronin-Fenton DP, Murray LJ, Whiteman DC, et al. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: A pooled analysis. Eur J Cancer 2010; 46:2067-2076.
17. Cheung WY, Zhai R, Bradbury P, et al. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer 2012; 131:2478-2486.
18. Su Z, Gay L, Strange A, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012; 44:1131-1136. doi: 10.1038/ng.2408.
19. Levine DM, EkWE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013; 45:1487-1493.
20. Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76:1087-1094.
21. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63:7-42.
22. Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2012; 157:808-816.
23. Thrift AP, Kendall BJ, Pandeya N, et al., Study of Digestive H. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res 2012; 5:1115-1123.
24. Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013; 11:138.e2-144.e2.
25. Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013; 108:353-362.
26. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93:358-366.
27. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337-347.
28. Abrams JA, Sharaiha RZ, Gonsalves L, et al. Dating the rise of esophageal adenocarcinoma: Analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol Biomarkers Prev 2011; 20:183-186.
29. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119:1149-1158.
30. Edgren G, Adami H-O, Weiderpass Vainio E, Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62:1406-1414.
31. Kroep S, Lansdorp-Vogelaar I, Rubenstein J, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the Unites States, Spain and the Netherlands. Am J Gastroenterol 2014; 109:336-343.
32. Kong CY, Nattinger KJ, Hayeck TJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev 2011; 20:2450-2456.
33. Tran B, Lucas R, Kimlin M, et al. Association between ambient ultraviolet radiation and risk of esophageal cancer. Am J Gastroenterol 2012; 107:1803-1813.
34. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2013. doi: 10.1136/gutjnl-2012-304269.